Sriram Ryali, Chief Financial Officer at Eiger BioPharmaceuticals, Inc. (EIGR), bought 1,250 shares at $11.08 ($14K) on 2019-04-22, disclosed to the SEC on 2019-04-22.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| EIGR | SELL | 2022-03-14 | $13K | — | Filing → |